However, a combination therapy with drugs like Dupulimab (targets the receptor complex common both IL-4 and IL-13) [53] and an anti-IL-5 mAb could synergistically curb the mechanisms of in situ eosinophilia plausibly altered in severe asthmatics, that render the airways susceptible to maintain the clinical symptoms. The gene discussed is IL5; the disease is Increased total eosinophil count.